Bellerophon Therapeutics, which is developing drug-device combination therapies for pulmonary and cardiac diseases, filed on Tuesday with the SEC to raise up to $69 million in an initial public offering.
Bellerophon was spun out of Ikaria in February 2014 as a special dividend to existing stockholders, shortly before Ikaria's non-biotech business was acquired by Madison Dearborn for $1.6 billion. Ikaria had originally intended to go public in November 2010 but withdrew its offering.
The Hampton, NJ-based company, which was spun out of Ikaria in 2014, plans to list on the NASDAQ under the symbol BLPH. Bellerophon Therapeutics initially filed confidentially on May 14, 2014. Leerink Partners and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
